✦ LIBER ✦

PDB4 THE HEALTH-ECONOMIC IMPLICATIONS OF THE “IRBESARTAN IN DIABETIC NEPHROPATHY TRIAL” (IDNT) IN FRANCE AND BELGIUM

✍ Scribed by AJ Palmer; L Annemans; S Roze; M Lamotte; C Guilhaume; S Gabriel; P Carita; R Chen; T Simon; R Rodby; DJ Cordonnier

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An economic evaluation of the Irbesartan

✍ Palmer, A J; Annemans, L; Roze, S; Lamotte, M; Rodby, R A; Bilous, R W 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 111 KB

341 Complications of Chronic Kidney Dise

✍ Gautham Viswanathan; Hocine Tighiouart; Paul Muntner; Julia Lewis; Mark Sarnak; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 191 KB

Cardiovascular outcomes in the Irbesarta

✍ T. Berl; L.G. Hunsicker; J.B. Lewis 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Impact of irbesartan, blood pressure con

✍ Hunsicker, Lawrence G.; Atkins, Robert C.; Lewis, Julia B.; Braden, Gregory; de 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 45 KB

Independent and Additive Impact of Blood

✍ Pohl, M. A. 📂 Article 📅 2005 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 385 KB

Estimated GFR Decline as a Surrogate End

✍ Lambers Heerspink, Hiddo J.; Weldegiorgis, Misghina; Inker, Lesley A.; Gansevoor 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 630 KB